sham Corp ., Arlington Heights, IL) or [ 62P,]orthophosphate (500 uCi). After a 5-h incubation, the cells were washed several times and lysed as described previously (7) . The cell lysate was precleared by absorption on Staphylococcus aureus and nonimmune serum. Equal amounts of labeled protein were then precipitated with mAb PAWL SDS-PAGE was performed according to Laemmli (36) . Precipitated proteins were visualized by autoradiography .
Inhibition of New Protein Synthesis . K562 cells were seeded at 4 x 10 5 cells/ml in a medium with 10% FCS 4 h before treatment with the protein synthesis inhibitor cycloheximide (CHX) (Sigma Chemical Co .) . At 0 h, CHX was added to the culture medium to a final concentration of 20 ug/ml . After 3 h the cells were washed two times in PBS and RNA was extracted.
DNA and RNA Isolations . Extraction of genomic DNA from cell lines was performed by lysing the cells with 3 % NP-40 and digesting the nuclei for 16 h at 50°C with proteinase K (Bethesda Research Laboratories, Bethesda, MD) (37) . The DNA was precipitated by adjustment of the solution to a final concentration of 2 M ammonium acetate and 875 subsequent addition of 1 vol isopropanol, followed by several rinses in 2 M ammonium acetate/80% ethanol, and 80% ethanol, as described by Hardy et al. (38) .
Total cellular RNA was extracted from cell lines and fresh human hematopoietic cells by the hot phenol method (37) . Briefly, cells were lysed at 60°C in guanidine isothiocyanate (Eastman Kodak Co., Rochester, NY) and extracted into phenol-chloroform . After several extractions the solution was precipitated with 2 vol ethanol . The precipitate was redissolved and digested with proteinase K for 2 h at 37'C. After several subsequent extractions in phenol-chloroform and chloroform, the aqueous phase was again precipitated with 2 vol ethanol .
Southern and Northern Blot Analyses. Restriction endonuclease digestions of genomic DNA were performed following manufacturer specifications . For methylation studies, 5-10X excess of Hpa 11 and Hha I (Boehringer Mannheim Biochemicals, Indianapolis, IN) was used for digestion, and plasmid DNA was added to aliquots of the reaction mix to monitor completeness of digestion. DNA was size fractionated on Tris-acetate or trisborate agarose gels. Total RNA was size fractionated on denaturing formaldehyde gels as described (37) . Nucleic acids were transferred to nylon-based filters (NCI; Biodyne, Irvine, CA) . Hybridization with GYP-oligolabeled (39) p53-specific probes was carried out as described (37) ; filters were rinsed to a final stringency of 0.25X SSC (DNA filters) or 0.1 X SSC (RNA filters) at 65°C for 15 min (1X SSC : 0.15 mol/liter NaCl; 0.015 mol/liter trisodium citrate).
DNA Transfection and CAT Assay. The BV173 lymphoid and K562 myeloid cell lines were transfected by a modification of the DEAE-dextran method (40) . Briefly, 10' cells were washed four times with serum-free medium and incubated for 4.5 h in 10 ml serumfree medium with 0.25 mg/ml DEAE-Dextran (Sigma Chemical Co.), 0.1 M Tris (pH 7.3), 10-4 M chloroquin (Sigma Chemical Co.), and 10 Wg of plasmid DNA. The cells were washed and incubated in a medium with 10% FCS for 42 h, then lysed by freezethawing, and cell extract was used to acetylate ['4Clchloramphenicol (Amersham Corp.). Labeled chloramphenicol and its acetylated forms were separated by ascending silica gel thin layer chromatography (TLC) (with solvent chloroform/methanol 95 :5) and visualized by autoradiography.
Results
Expression ofp53 mRNA and Protein in CML Cell Lines and Cells from Patients with CML. A number of leukemic cell lines established from patients with CML were screened by Northern blot analysis for expression of p53 mRNA ( Fig. 1 A, Table 1 ). T-lymphocytic S-LB1, immortalized by infection with HTLV-1, was used as a positive control and the HL-60 myeloid cell line (with a deletion of the p53 gene) served as negative control . The p53 mRNA was detected in all the lymphoid lines, which includes SK-CML8-Bt(9 ;22), MBL, BV 173, SK-CML8-BN and S-LB 1 ( Fig. 1 A, lanes 1-3, 8 , and 10), and EM-2 and EM-3 myeloid lines (lanes 5 and 6). Negligible p53 mRNA was detectable in the myeloid CML cell lines K562 and KCI-22 (lanes 4 and 7). The p53 mRNA was not detected in K562 cells even after treatment of the cells with an inhibitor of protein synthesis (cycloheximide) (data not shown) . The filter was rehybridized with c-myc (Fig.  I B) . HL-60 cells expressed the largest amounts of c-myc mRNA, followed by EM-2, EM-3 (Fig. 1B, lanes 7-9) , KCI-22, and K562 . Small to undetectable amounts of c-myc mRNA were found in the lymphoid lines.
We studied the ability of the CML cell lines to synthesize p53 protein by metabolic labeling and immunoprecipitation, using the mAb PAb421 (Fig. 2) . The p53 protein was detected in the lymphoid cell lines BV 173, NALM-1, MBL (lanes [4] [5] [6] . No p53 protein was detected in the myeloid lines including K562, EM-2, EM-3 (lanes 7-9), and KCI-22 (data not shown). Of note, in lane 6 (MBL), The characteristics or the cell lines are provided in their corresponding references . Abbreviations: NT, not tested ; ±, only trace amounts detectable . a 70-kD band is quite prominent. We noted this band to coprecipitate with p53 in five separate experiments; it is the correct molecular weight to be the major heat shock protein Hsp70. Prior studies have shown that the p53 protein can complex with this protein (41) .
p53 expression was also studied in two EBV-immortalized B lymphocyte lines that differ in the presence [SK-CML8-Bt(9 ;22)] or absence (SK-CML8-BN) of the Ph' chromosome . Both were established from a 63 yr old male patient with CML in the chronic phase (21) . The SK-CML8-Bt (9 ;22) malignant clone of the disease, while SK-CML8-BN was immortalized from the untransformed, normal B lymphocyte population . Northern blot analysis showed presence of p53 mRNA in both cell lines (Fig . 1, lanes 1 and 8) . Using metabolic labeling with [ s1p1]orthophosphate, we also detected synthesis of a phosphorylated p53 protein in both of these lines (Fig . 3, lanes 1, 2) .
We also performed Northern blot analysis of p53 expression in fresh CML cells from three patients in myeloid blast crisis and one patient in the chronic phase of Ph" CML (Table 11) . We found that p53 mRNA was expressed in myeloid cells from two patients in myeloid blast crisis and one patient in chronic phase, while no p53 mRNA could be detected in cells from patient 4 (Fig . 4,  lanes 1-4) . The amounts of mRNA expressed were comparable to that detected in the T-lymphocyte line S-LB1 (lane S) . HL-60 cells expressed no p53 mRNA (lane H).
Analysis of Expression of p53 mRNA in Ph" Somatic Hybrids and Their Parental Lines. Somatic hybrids (Dutko, Putko) formed between K562 (myeloid, p53 mRNA nonexpressor) and one of two lymphoid lines (Daudi, PUT ; p53 expres- sors) were used to study the mechanisms governing expression of p53 mRNA . In addition, we studied expression in a somatic hybrid (HP-1) between HL-60 (myeloid nonexpressor with loss of one and grossly rearranged remaining p53 allele) and PUT. The p53 mRNA was present in the lymphoid parental cells, PUT and Daudi ( Analysis of p53 protein synthesis in these lines and somatic hybrids by means of metabolic labeling and immunoprecipitation showed that all lines that expressed p53 mRNA also expressed p53 protein (Fig. 6) . Southern blot analysis of these cell lines using Eco RI digestion and probes detecting the 3' and 5' regions of the gene showed that the 3' region of p53 was grossly intact, except for the p53 deletion found in both HL-60, as described previously (10), and HP-1 (somatic hybrid of HL-60 and PUT) . Both showed a truncated 2.3-kb Eco RI fragment (Fig. 7) . The somatic hybrid HP-1 also retained the normal p53 alleles from the PUT parental line as demonstrated by the the presence of the normal 16-kb Eco RI band. The 5' region of all lines appeared grossly intact (data not shown) .
Activation of the p53 Promoter Linked to an Indicator Gene (CAT) in Both a p53 mRNA Expressor and Nonexpressor Line. Gene expression can be either positively or negatively regulated by the interaction of nuclear proteins with promoter sequences (42, 43) . We sought to study whether a difference could be detected in the ability of K562 (myeloid p53 nonexpressor) and BV173 (lymphoid p53 expressor) to activate the p53 promoter. To this end, two plasmid constructs (p53BXB and p53RXB) carrying p53 promoter sequences cloned in front of the CAT gene (33) were transfected into each cell type. Activation of the promoter was determined by assaying for CAT activity . The results are shown in Fig. 8 . Both p53/CAT constructs showed equal activity in each of the two cell lines (p53BXB and p53RXB in BV 173 : panel A, lanes 2 and 3, respectively ; p53BXB and p53RXB in K562; panel B, lanes 2 and 3, respectively) . No significant difference between the strength of the two p53/CAT constructs was observed . An overall stronger CAT enzyme activity in BV 173 than K562 was observed in repeated experiments and is most clearly reflected by the signal strength with pSV2-CAT (lane 1 of panels A and B). DNA Methylation Pattern in a p53 mRNA Expressor and Nonexpressor Cell Line . The pattern of demethylated CpG dinucleotides was studied in the p53 gene of BV 173 (p53 expressor, CML lymphoid line) and in K562 (p53 mRNA nonexpressor, CML myeloid line) . The DNA from both lines was digested with the methylcytosine-sensitive restriction enzymes Hpa II (recognition site CCGG) and Hha I (recognition site GCGC) and with the methylcytosine-insensitive enzyme Msp I (isoschizomer of Hpa 11, recognition sites CmCGG and CCGG) . Hybridization of a Southern blot containing these DNAs with the 3'-specific probe pR4-2 yielded a band >23 kb that was identical in size for both lines in Hpa II and Hha I digests (Fig . 9, lanes 1-4) . Msp I digests yielded a number of small bands of identical size in both cell lines (Fig . 9, lanes 5 and 6) . When studying the 5' portion of the gene using the clone pBT53 as probe, we detected a band of^-700 by in K562, BV173, and S-LB1 cells after digestion with either Hpa II or Msp I (Fig . 10, lanes 1-6) (inspection of the ethidium bromide-stained gel showed that in lane 6, less material was run, resulting in the faint 700-bp band in that lane) . Digesting the DNA of BV173, K562, and S-LB 1 with Hha 1 and probing the resulting Southern blot with pBT53, we found one band of "670 by in each of the digests (Fig. 10, lanes 7-9) . This finding indicates the presence of four demethylated CpG sites . The orientation of the fragments and the position of the restriction sites flanking them were deduced from the published sequence (33) and from double restriction enzyme digestions . The 700-bp Hpa II/Msp I band was diminished in size with Bam HI but not Xba 1, and double digestion with Hha I and Xba I yielded a smaller fragment of 325 by (data not shown) . Three of the demethylated sites map to a sequence in the promoter region starting -730 by upstream of the hypothetical cap site ; the fourth site of demethylation is located 85 by downstream of the cap site (Fig.  11) . The methylation status of the CCGG site 155 by downstream of the cap site could not be determined because the fragment size of 180 by was below our detection limit on Southern blot. Also, we did not evaluate other sites of demethylation upstream of the CCGG sequence at approximately -730 of the cap site .
Discussion
Prior studies by others (8, 9) as well as ourselves (7) have found that cells of lymphoid origin can express high levels of p53 protein, whereas cells of myeloid origin express negligible amounts of p53 . In the present study we investigated the p53 expression using CML cells as a model. This malignancy originates from a single pluripotent hematopoietic stem cell that can differentiate into either lymphoid or myeloid cells. We found that all lymphoid CML lines expressed p53 mRNA and protein. None of the myeloid lines expressed detectable p53 protein; and negligible levels of p53 mRNA were found in two myeloid CML lines K562 and KCI-22, even after treatment of K562 cells with CHX, an inhibitor of protein synthesis. Accumulation of mRNA coding for other transiently expressed oncogenes and growth factors is increased when the cells are exposed to an inhibitor of protein synthesis (44, 45) . Surprisingly, however, two myeloid CML lines (EM-2, EM-3) and primary leukemic cells from three of four patients with CML expressed p53 mRNA . Our present results, taken together with our prior findings, suggest that two groups of myeloid leukemic lines can be found with respect to expression of p53 : those that express negligible p53 mRNA and protein (e.g., K562, KCI-22, KG-1, ML-3, U937, A7) and those that accumulate p53 transcripts but no protein (EM-2, EM-3). Possibly, cells belonging to the latter group synthesize an antigenically altered p53 protein that is not recognized by the PAb421 mAb. This phenomenon has been described in HeLa cells (46) . The appearance of p53 in myeloid cells might mean that expression of the gene is not regulated normally in CML.
To study the regulatory mechanisms responsible for p53 expression, we examined two somatic hybrid lines that were the fusion products of K562 (myeloid, p53 RNA nonexpressor) and either of two lymphoid lines (p53 expressors) . Our results indicate that p53 expression is a dominant feature, with the somatic hybrids expressing both p53 mRNA and protein . This suggests that lack of p53 expression in K562 is probably not the result of an inhibitory transacting protein.
We also studied the ability of the p53 mRNA expressor and nonexpressor CML lines to activate the p53 promoter attached to the CAT gene. Two plasmid constructs containing 350 by and 2.4 kb of the 5' p53 region (part of exon 1 and 5' flanking sequences, both shown to contain the p53 promoter [33] ) were transfected into K562 (myeloid, p53 nonexpressor) and BV 173 (lymphoid, p53 expressor) . We found that both of these constructs were about equally active in BV 173 and K562, indicating that the lack of p53 expression by K562 was not because of either the lack of a positive or presence of a negative trans-activator of p53.
The distribution pattern of demethylated CpG dinucleotides is a feature of genes that is correlated with their expression (47, 48) . In DNA of vertebrates, cytosine is methylated up to 90% of the time, and this modification is almost 883 always found in the sequence mCpG. Demethylation of this sequence at certain sites in the gene may be necessary for gene expression ; and for a number of tissues, this demethylation occurs in genes actively expressed, whereas the same sites are methylated in nonexpressing tissues (47) . For many genes, however, no differences in the methylation pattern between expressing and nonexpressing tissues have been detected. Of these, so-called "housekeeping genes" (genes expressed in a variety of tissues often at a variety of stages of differentiation) have a specific distribution pattern of methylated and demethylated cytosine/ guanine dinucleotides (CpGs) (48) . Sites of demethylation are clustered in a CpGrich 5' region of an otherwise hypermethylated and CpG-poor gene (48, 49) . These clusters have been termed Hpa 11 Tiny Fragments (HTF) islands (49) . Our analysis showed no difference in the methylation pattern of BV 173 (lymphoid, p53 expressor) and K562 (myeloid, p53 nonexpressor) . Furthermore, we found that the p53 gene is highly methylated over its entire coding region but demethylated at least in four sites in and 5' of the noncoding first exon . This pattern of hypomethylation is reminiscent of a HTF island in a housekeeping gene . We have found the same pattern of methylation in another system of differential p53 expression, quiescent (p53 mRNA nonexpressor) and actively proliferating peripheral blood T lymphocytes (p53 expressor) (manuscript in perparation) .
Based on the notion that p53 and c-myc may have similar functions, and the observation that HL-60 cells lack p53 expression but exhibit c-myc amplification, Wolf and Rotter (10) speculated that lack of p53 expression may be compensated by overexpression of c-myc. Our results are consistent with this notion . All myeloid lines lacking p53 protein synthesis (as detected by PAb421) strongly express c-myc mRNA, while all lymphoid lines express p53 protein but negligible amounts of c-myc mRNA . Cells of none of the lines lack expression of both p53 and c-myc (see Table 1 ) . Summary The p53 is a nuclear protein that is associated with normal cellular proliferation and can cooperate with Ha-ras in causing cellular transformation in vitro . Lineage association is known to exist between p53 expression and normal lymphopoiesis, but not myelopoiesis . We studied the expression of p53 using chronic myelogenous leukemia (CML) cell lines, somatic hybrids of these cells, and leukemic cells from CML patients . Lymphoid CML lines expressed both p53 mRNA and protein . We also analyzed p53 synthesis by two B-lymphoid lines from the same CML patient ; cells of one line were derived from the neoplastic clone, cells of the other were derived from the normal clone . Both synthesized equal amounts of a phosphorylated p53 protein . None of the myeloid CML lines expressed detectable p53 protein and two of four expressed negligible p53 mRNA . Two other myeloid CML lines and myeloid cells from three of four patients expressed p53 mRNA . These findings suggest that expression of the gene is not regulated normally in CML . Several approaches were pursued to explore the differential expression of p53 . Southern blot analyses showed no gross alterations in the p53 gene from cells of either the expressing or the nonexpressing lines . No difference in the pattern of demethylated CpG sites was noted in the region of the p53 gene in cells from K562 (myeloid p53 nonexpressor) and in BV 173 (lymphoid 884 p53 IN CHRONIC MYELOCENOUS LEUKEMIA p53 expressor) . The sites of demethylation clustered in and around the p53 promoter in both cell lines . Somatic hybrids formed between a p53 mRNA nonexpressor myeloid line (K562) and the parental p53 expressor lymphoid lines (Daudi, PUT) produced p53 mRNA and protein, suggesting that p53 is a dominantly expressed protein and that lack of expression in myeloid cells is not mediated by a trans-acting negative regulatory protein . DNA transfection experiments performed using the indicator gene chloramphenicol acetyltransferase attached to promoter sequences of p53 showed that these constructs were equally activated in BV 173 (p53 expressor) and K562 (p53 mRNA nonexpressor) . The mechanism of p53 regulation in CML remains unclear.
